Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates. | Available online http content 13 6 R193 Research Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration a randomized cross-over trial comparing two hemofiltration rates Heleen M Oudemans-van Straaten1 3 Muriel van Schilfgaarde2 Pascal J Molenaar2 Jos PJ Wester1 and Anja Leyte2 Department of Intensive Care Medicine Onze Lieve Vrouwe Gasthuis Oosterpark 9 1 091 AC Amsterdam The Netherlands department of Clinical Chemistry Onze Lieve Vrouwe Gasthuis Oosterpark 9 1091 AC Amsterdam The Netherlands institutional address Onze Lieve Vrouwe Gasthuis PO Box 95500 1091 AC Amsterdam The Netherlands Corresponding author Heleen M Oudemans-van Straaten Received 6 Aug 2009 Revisions requested 2 Oct 2009 Revisions received 28 Oct 2009 Accepted 3 Dec 2009 Published 3 Dec 2009 Critical Care 2009 13 R193 doi cc8191 This article is online at http content 13 6 R1 93 2009 Oudemans-van Straaten et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Renal insufficiency increases the half-life of low molecular weight heparins LMWHs . Whether continuous venovenous hemofiltration CVVH removes LMWHs is unsettled. We studied hemostasis during nadroparin anticoagulation for CVVH and explored the implication of the endogenous thrombin potential ETP . Methods This cross-over study performed in a 20-bed teaching hospital ICU randomized non-surgical patients with acute kidney injury requiring nadroparin for CVVH to compare hemostasis between two doses of CVVH filtrate flow was initiated at 4 L h and converted to 2 L h after 60 min in group 1 and vice versa in group 2. Patients received nadroparin 2850 IU . .
